Xymoheal Tablet contains Trypsin Chymotrypsin (100000 AU), a proteolytic enzyme combination widely used for its anti-inflammatory, anti-edematous, and fibrinolytic properties. This medication is indicated for the management of acute and chronic inflammatory conditions, including post-traumatic swelling, surgical edema, and soft tissue injuries. Trypsin and Chymotrypsin act synergistically to degrade necrotic proteins and fibrin clots, facilitating the resolution of inflammation and promoting tissue repair. Xymoheal Tablet is commonly prescribed to reduce pain and accelerate healing in musculoskeletal disorders, such as sprains, strains, and post-operative recovery. The enzyme preparation enhances microcirculation and modulates the inflammatory response by decreasing the release of pro-inflammatory mediators. It is generally well tolerated, with minimal adverse effects; however, hypersensitivity reactions may occur in rare cases. Xymoheal should be administered under medical supervision, with dosage tailored according to the severity of the condition and patient response. Caution is advised in patients with bleeding disorders or those on anticoagulant therapy due to the potential risk of increased bleeding. Overall, Xymoheal Tablet serves as an effective adjunct in the management of inflammation and edema, contributing to improved patient outcomes in various clinical scenarios.